Changwei Huang

Title: Changwei Huang: Innovator in Pharmaceutical Chemistry

Introduction

Changwei Huang is a notable inventor based in Dongguan, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that address various medical conditions. With a total of two patents to his name, Huang's work focuses on innovative solutions for treating diseases related to bone resorption and high blood uric acid levels.

Latest Patents

Huang's latest patents include "Cathepsin K inhibitors and application thereof." This invention relates to a class of compounds designed to treat or prevent cathepsin-dependent diseases, specifically targeting cathepsin K. The compounds and compositions developed can serve as bone resorption inhibitors, offering potential treatments for associated diseases.

Another significant patent is for "Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof." This patent provides carboxy-substituted (hetero)aryl derivatives and pharmaceutical compositions that inhibit xanthine oxidase and urate anion transporter 1. These compounds are particularly useful in treating or preventing diseases associated with elevated blood uric acid levels in mammals, especially humans.

Career Highlights

Throughout his career, Changwei Huang has worked with several prominent companies in the pharmaceutical industry. Notably, he has been associated with Sunshine Lake Pharma Co., Ltd. and North & South Brother Pharmacy Investment Company Limited. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Huang has collaborated with various professionals in his field, including Xiaojun Wang and Yingjun Zhang. These collaborations have likely enhanced his research and development efforts, leading to innovative solutions in pharmaceutical chemistry.

Conclusion

Changwei Huang is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in treating critical health conditions. His patents reflect a commitment to innovation and improving patient outcomes through targeted therapies.